Dr. Uma Borate, MD
Claim this profileOhio State University Comprehensive Cancer Center
Studies Acute Myeloid Leukemia
Studies Acute Myelogenous Leukemia
17 reported clinical trials
31 drugs studied
About Uma Borate, MD
Education:
- Obtained MD from Ohio State University College of Medicine in 2015.
- Completed Residency in Internal Medicine at The Ohio State University Wexner Medical Center in 2018.
- Finished Fellowship in Hematology and Oncology at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in 2021.
Experience:
- Specializes in Internal Medicine, Hematology, and Oncology.
- Trained at The Ohio State University Comprehensive Cancer Center.
Area of expertise
1Acute Myeloid Leukemia
CD33 positive
FLT3 positive
hydroxyurea
2Acute Myelogenous Leukemia
CD33 positive
FLT3 positive
RARA positive
Affiliated Hospitals
Clinical Trials Uma Borate, MD is currently running
Epoetin Alfa vs Luspatercept
for Myelodysplastic Syndrome
This trial is testing two treatments, Luspatercept and epoetin alfa, to see which is better for treating anemia in adults with certain types of myelodysplastic syndromes (MDS). The participants have not used similar treatments before and do not need regular blood transfusions. Luspatercept helps red blood cells mature, while epoetin alfa increases their production.
Recruiting2 awards Phase 3
SNDX-5613 + Gilteritinib
for Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of SNDX-5613 and gilteritinib for treating patients with acute myeloid leukemia that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and has a mutation in the FLT3 gene along with either a mutation in the NMP1 gene or a type of mutation called a rearrangement in the MLL gene. SNDX-5613 is in a class of medications called menin inhibitors. It works by blocking the action of mutated MLL and NMP1 proteins that signal cancer cells to multiply. Gilteritinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of mutated FLT3 proteins that signal cancer cells to multiply. Giving SNDX-5613 with gilteritinib may be safe, tolerable and/or effective in treating patients with relapsed/refractory FLT3 mutated acute myeloid leukemia.
Recruiting1 award Phase 1
More about Uma Borate, MD
Clinical Trial Related4 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Uma Borate, MD has experience with
- Azacitidine
- Venetoclax
- Cytarabine
- Canakinumab
- Gilteritinib
- SNDX-5613
Breakdown of trials Uma Borate, MD has run
Acute Myeloid Leukemia
Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Myeloproliferative Disorder
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Uma Borate, MD specialize in?
Uma Borate, MD focuses on Acute Myeloid Leukemia and Acute Myelogenous Leukemia. In particular, much of their work with Acute Myeloid Leukemia has involved CD33 positive patients, or patients who are FLT3 positive.
Is Uma Borate, MD currently recruiting for clinical trials?
Yes, Uma Borate, MD is currently recruiting for 7 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Uma Borate, MD has studied deeply?
Yes, Uma Borate, MD has studied treatments such as Azacitidine, Venetoclax, Cytarabine.
What is the best way to schedule an appointment with Uma Borate, MD?
Apply for one of the trials that Uma Borate, MD is conducting.
What is the office address of Uma Borate, MD?
The office of Uma Borate, MD is located at: Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States. This is the address for their practice at the Ohio State University Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.